What Is GLP-1? How GLP-1 Medications Work for Weight Loss

GLP-1: The Hormone Behind the Medications

GLP-1 stands for glucagon-like peptide-1. Your intestinal L-cells secrete it within minutes of eating, and it acts on receptors in the pancreas, stomach, and brain to coordinate how your body handles food. The hormone belongs to a class called incretins, which account for roughly 50 to 70% of the insulin response after an oral glucose load [1].

Where GLP-1 Is Produced

L-cells concentrated in the ileum and colon release GLP-1 when nutrients (especially carbohydrates and fats) reach the lower gut. A smaller "early phase" release also occurs through neural signaling before nutrients physically arrive at these cells [2]. This two-phase release pattern explains why meal composition and eating speed both influence how much GLP-1 your body produces.

Why Native GLP-1 Disappears Quickly

Natural GLP-1 has a half-life of about 2 minutes. The enzyme dipeptidyl peptidase-4 (DPP-4) cleaves it almost immediately after secretion [1]. That rapid degradation is why DPP-4 inhibitors (like sitagliptin) were developed first. They modestly raise GLP-1 levels by blocking the enzyme. GLP-1 receptor agonists took a different approach: they engineered molecules that resist DPP-4 breakdown entirely, creating drug concentrations far above what the body produces on its own.

How GLP-1 Receptor Agonists Produce Weight Loss

These medications work through at least three simultaneous pathways: appetite suppression in the brain, delayed stomach emptying, and improved metabolic signaling. Each pathway contributes to a sustained caloric deficit without the compensatory hunger spikes that undermine conventional dieting.

Central Appetite Suppression

GLP-1 receptors in the hypothalamus and brainstem regulate satiety. When a GLP-1 receptor agonist binds these receptors, it reduces hunger signals and increases the feeling of fullness after smaller meals. Neuroimaging studies show that semaglutide decreases activity in brain regions associated with food craving and reward processing [3]. Patients on these medications consistently report less food preoccupation, not just smaller appetites.

Delayed Gastric Emptying

GLP-1 receptor agonists slow the rate at which food leaves the stomach, extending the period of physical fullness. Gastric emptying half-time increases by roughly 30 to 60 minutes during active treatment with semaglutide [4]. This effect tends to partially attenuate over months, which is one reason nausea typically improves after the first 4 to 8 weeks of dose titration.

Metabolic Effects Beyond Appetite

The pancreatic effects of GLP-1 receptor agonists include glucose-dependent insulin secretion and suppression of glucagon release. These actions improve insulin sensitivity and reduce fasting glucose. In patients with type 2 diabetes, this dual hormonal correction often reduces HbA1c by 1.0 to 1.8 percentage points [5]. For patients without diabetes, GLP-1 receptor agonists may prevent progression from prediabetes to diabetes while producing weight loss.

Clinical Trial Evidence for Weight Loss

The evidence base for GLP-1 receptor agonist weight loss comes from large, randomized, double-blind trials. Two drug programs have generated the most data: semaglutide (Novo Nordisk's STEP program) and tirzepatide (Lilly's SURMOUNT program).

The STEP Trial Program (Semaglutide)

In STEP-1 (N=1,961), participants without diabetes who received semaglutide 2.4 mg weekly lost a mean of 14.9% of their body weight at 68 weeks, compared to 2.4% in the placebo group [6]. That translates to roughly 15.3 kg (33.7 lb) of absolute weight loss. STEP-2 enrolled participants with type 2 diabetes and showed 9.6% weight loss with the same dose, confirming that diabetes reduces but does not eliminate the weight loss effect [7].

STEP-3 combined semaglutide with intensive behavioral therapy and reported 16.0% weight loss at 68 weeks [8]. STEP-5 extended follow-up to 104 weeks, demonstrating that weight loss was maintained at 15.2% in the semaglutide group [9].

The SURMOUNT Trial Program (Tirzepatide)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates receptors for both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. In SURMOUNT-1 (N=2,539), participants without diabetes who received tirzepatide 15 mg lost a mean of 22.5% body weight at 72 weeks, vs. 2.4% with placebo [10]. The 10 mg dose produced 19.5% loss and the 5 mg dose produced 15.0% loss.

Dr. Ania Jastreboff, the principal investigator of SURMOUNT-1 and an obesity medicine specialist at Yale, stated: "These are the largest reductions in body weight that have been achieved with a medication in an obesity trial to date" [10].

Head-to-Head and Real-World Data

Real-world evidence from the TRIBUTE study and large retrospective cohort analyses suggests that clinical practice weight loss averages 10 to 12% at 12 months for semaglutide, somewhat lower than trial results due to dose titration variability and adherence differences [11]. The gap between trial efficacy and real-world effectiveness is common across all weight management therapies.

FDA-Approved GLP-1 Medications for Weight Loss

Not every GLP-1 receptor agonist carries an FDA-approved indication for weight management. The distinction between diabetes-approved and obesity-approved formulations matters for insurance coverage, dosing, and prescribing.

Approved for Chronic Weight Management

Semaglutide 2.4 mg (Wegovy): FDA-approved in June 2021 for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Administered as a weekly subcutaneous injection. Dose is titrated over 16 weeks from 0.25 mg to the maintenance dose of 2.4 mg [12].

Tirzepatide (Zepbound): FDA-approved in November 2023 for the same BMI criteria. Available in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg weekly subcutaneous injection. Titration follows a minimum 4-week interval per dose step [13].

Liraglutide 3.0 mg (Saxenda): FDA-approved in 2014, this older daily injection produces about 5 to 8% mean weight loss. It remains available but is prescribed less frequently since weekly options arrived [14].

Approved for Diabetes Only (Used Off-Label for Weight)

Semaglutide 0.5 mg, 1.0 mg, and 2.0 mg (Ozempic) are approved for type 2 diabetes. Many prescribers use Ozempic off-label for weight loss when Wegovy is unavailable or not covered by insurance. The maximum Ozempic dose (2.0 mg) is lower than the Wegovy maintenance dose (2.4 mg), which may produce slightly less weight loss.

Dulaglutide (Trulicity), exenatide (Bydureon), and lixisenatide (Adlyxin) are also GLP-1 receptor agonists approved only for diabetes.

Side Effects and Safety Profile

GLP-1 receptor agonists share a predictable side effect profile dominated by gastrointestinal symptoms. Most adverse events are dose-related and improve with continued use.

Gastrointestinal Effects

Nausea affects 40 to 44% of patients starting semaglutide 2.4 mg, but the rate of treatment discontinuation due to GI side effects is only about 7% in clinical trials [6]. Vomiting (24%), diarrhea (30%), and constipation (24%) are also common during the titration phase. Slower dose escalation reduces the severity of these symptoms.

Serious but Rare Adverse Events

Pancreatitis has been reported in <0.3% of patients across the STEP and SURMOUNT programs [6][10]. Gallbladder events (cholelithiasis, cholecystitis) occur at higher rates than placebo, with an incidence of about 1.6% in STEP-1 vs. 0.7% with placebo [6]. Rapid weight loss of any kind increases gallstone risk, so this finding is not unique to GLP-1 receptor agonists.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity notes: "The benefits of 15% or greater weight loss on cardiometabolic risk factors substantially outweigh the risks of GI adverse events in most patients with obesity" [15].

Thyroid Safety

GLP-1 receptor agonists carry a boxed warning about medullary thyroid carcinoma (MTC) based on rodent studies showing C-cell tumors. Human data across more than 10 years of use have not confirmed this risk. The SELECT trial (N=17,604), which followed patients for a mean of 39.8 months, reported no increase in thyroid cancer incidence with semaglutide compared to placebo [16].

What Happens When You Stop a GLP-1 Medication

Weight regain after discontinuation is the most discussed limitation of these drugs. The STEP-1 extension trial showed that participants who stopped semaglutide at 68 weeks regained approximately two-thirds of their lost weight by week 120 [17]. This pattern mirrors what happens when any chronic disease treatment is discontinued.

Why Regain Occurs

Obesity involves persistent neurohormonal adaptations. After weight loss, ghrelin (the hunger hormone) increases, leptin decreases, and resting metabolic rate drops. These compensatory mechanisms exist regardless of how the weight was lost. GLP-1 receptor agonists suppress these signals during treatment, but the signals return when the medication stops [17].

Long-Term Treatment Considerations

The American Association of Clinical Endocrinology (AACE) and the Obesity Medicine Association both classify obesity as a chronic disease requiring ongoing treatment [18]. For many patients, GLP-1 receptor agonist therapy may be long-term, similar to how statins treat hyperlipidemia or antihypertensives treat high blood pressure. Some clinicians trial dose reduction (e.g., stepping down from 2.4 mg to 1.7 mg of semaglutide) to find the minimum effective dose for weight maintenance.

Cardiovascular Benefits Beyond Weight Loss

GLP-1 receptor agonists reduce cardiovascular events independently of weight loss, a finding that has changed how cardiologists and endocrinologists think about these drugs.

The SELECT Trial

SELECT (N=17,604) enrolled adults with established cardiovascular disease, BMI ≥27, and no diabetes. Semaglutide 2.4 mg reduced the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 20% compared to placebo (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [16]. This was the first trial to show cardiovascular risk reduction with a GLP-1 receptor agonist in a non-diabetic population.

Mechanisms of Cardiovascular Protection

The cardioprotective effects likely involve reduced systemic inflammation, improved endothelial function, lower blood pressure (mean reduction of 3 to 5 mmHg systolic), and favorable changes in lipid profiles [16]. C-reactive protein (CRP), a marker of inflammation, dropped by approximately 40% in the semaglutide group in SELECT.

Who Is Eligible for GLP-1 Medication for Weight Loss

Eligibility criteria are straightforward. The FDA-approved indications require a BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea [12][13].

Who Should Not Take These Medications

Contraindications include a personal or family history of MTC, multiple endocrine neoplasia syndrome type 2 (MEN2), and known hypersensitivity to the active ingredient. GLP-1 receptor agonists should not be used during pregnancy. Semaglutide should be discontinued at least 2 months before a planned pregnancy due to its long half-life of approximately 7 days [12].

Insurance and Access Barriers

Coverage varies widely. Many commercial plans now cover Wegovy and Zepbound for obesity, but Medicare Part D is still prohibited by law from covering anti-obesity medications. Out-of-pocket costs without insurance range from $900 to $1,350 per month for brand-name products [19]. Manufacturer savings programs, compounding pharmacies, and prior authorization pathways can reduce costs, though availability fluctuates.

How GLP-1 Medications Are Started and Dosed

All GLP-1 receptor agonists for weight management use a slow dose-titration schedule to minimize gastrointestinal side effects. Skipping titration steps increases nausea and vomiting rates significantly.

Semaglutide (Wegovy) Titration

The titration schedule spans 16 weeks: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then 2.4 mg maintenance. Patients who cannot tolerate 2.4 mg may stay at 1.7 mg [12]. Injections are given subcutaneously in the abdomen, thigh, or upper arm, on the same day each week.

Tirzepatide (Zepbound) Titration

Tirzepatide starts at 2.5 mg weekly for 4 weeks, then increases to 5 mg. From there, the dose can be increased by 2.5 mg increments every 4 weeks up to a maximum of 15 mg weekly [13]. Many patients achieve satisfactory weight loss at 10 mg without needing the full 15 mg dose.

Patients should eat slowly, choose smaller portions, stop eating at the first sign of fullness, and stay hydrated during titration. These behavioral adjustments reduce GI symptoms more than any antiemetic medication.